Clinical trial NCT05622162 - References

Prostate Cancer — Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7

Citation(s)

•   Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U
  The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in t
•   Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U
  Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recur
•   Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I
  18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012 Mar;15(1):45-55. doi: 10.1038/pcan.2011.35. Epub 2011 Aug 16. Revie
•   Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W
  Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA ki
•   Castellucci P, Fanti S
  Prostate cancer: Identifying sites of recurrence with choline-PET-CT imaging. Nat Rev Urol. 2015 Mar;12(3):134-5. doi: 10.1038/nrurol.2014.321. Epub 2014 Dec 2.
•   Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Hautekiet A, Maes G, Ost P
  Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014 Jun 12;9:135. doi: 10.1186
•   Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, Täger P, Hammes J, Heidenreich A, Neumaier B, Drzezga A, Dietlein M
  An (18)F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experien
•   Eiber M, Kroenke M, Wurzer A, Ulbrich L, Jooß L, Maurer T, Horn T, Schiller K, Langbein T, Buschner G, Wester HJ, Weber W
  (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2020 May;
•   Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S
  Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011 Nov;80(2):e50-6. doi: 10.1016/j.ejrad.2010.07.023. Epub 2010 Aug 25. Review.
•   Galgano SJ, Valentin R, McConathy J
  Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer. Transl Androl Urol. 2018 Sep;7(Suppl 4):S462-S476. doi: 10.21037/tau.2018.06.09. Review.
•   Giovacchini G, Giovannini E, Borsò E, Lazzeri P, Riondato M, Leoncini R, Duce V, Conti E, Picchio M, Ciarmiello A
  Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a
•   Grummet J, Eggener S
  Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021. Eur Urol. 2022 Feb;81(2):218. doi: 10.1016/j.eururo.2021.11.025. Epub 2021 Dec 9.
•   Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology
  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curati
•   Kroenke M, Wurzer A, Schwamborn K, Ulbrich L, Jooß L, Maurer T, Horn T, Rauscher I, Haller B, Herz M, Wester HJ, Weber WA, Eiber M
  Histologically Confirmed Diagnostic Efficacy of (18)F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostat
•   Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, Brunocilla E, Fantini L, Costa S, Ferretti A, Colletti PM, Rubello D, Fanti S
  The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer
•   Ménard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, Jaffray DA, Chung P, Brock KK, Haider MA
  MR-guided prostate biopsy for planning of focal salvage
•   Natarajan A, Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, Shah S, Puranik A, Rangarajan V
  Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurre
•   Oh SW, Cheon GJ
  Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean J Radiol. 2018 Sep-Oct;19(5):819-831. doi: 10.3348/kjr.2018.19.5.819. Epub 2018 Aug 6. Review.
•   Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N
  Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systema
•   Perks J, Benedict S
  MO-F-BRCD-02: SBRT (Part 2): Physics and Quality Assurance Updates. Med Phys. 2012 Jun;39(6Part21):3873. doi: 10.1118/1.4735813.
•   Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M
  Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061. doi: 10.1
•   Rajasekaran AK, Anilkumar G, Christiansen JJ
  Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005 May;288(5):C975-81. Review.
•   Samper Ots P, Luis Cardo A, Vallejo Ocaña C, Cabeza Rodríguez MA, Glaria Enríquez LA, Couselo Paniagua ML, Olivera Vegas J
  Diagnostic performance of (18)F-choline PET-CT in prostate cancer. Clin Transl Oncol. 2019 Jun;21(6):766-773. doi: 10.1007/s12094-0
•   Schulz KF, Altman DG, Moher D
  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010 Jul;1(2):100-7. doi: 10.4103/0976-500X.72352.
•   Zlatopolskiy BD, Endepols H, Krapf P, Guliyev M, Urusova EA, Richarz R, Hohberg M, Dietlein M, Drzezga A, Neumaier B
  Discovery of (18)F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. J Nucl Med. 2019 Jun;60(6):817-823. doi: 10.2

Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent

Details for clinical trial NCT05622162